Reading the tape
NASDAQ: VCYT
Veracyte, Inc.
Healthcare · Biotechnology
Market Cap
$2.67B
52w High
$50.71
52w Low
$22.61
P/E
39.92
Volume
729.14K
Outstanding Shares
79.79M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 6.8%Revenue (TTM): 16.01%FCF (TTM): 97.62%P/FCF: 0th pct
What changed
The stock rose 6.8% over the last year. Revenue grew 16.01% over the trailing twelve months. Operating margin moved from 3.62% to 9%. Free cash flow grew 97.62% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 9%. A decisive move in revenue — currently up 16.01% — would be the clearest signal to resolve the ambiguity.
Company profile
Veracyte, Inc. operates as a diagnostics company worldwide.
CEOMarc A. Stapley
SectorHealthcare
IndustryBiotechnology
Employees824
IPO dateOct 30, 2013
Valuation
Forward P/E—
EV/EBITDA33.31
Enterprise value$2.99B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth18.55%
Gross margin70.63%▲4.09%vs FY2024
Operating margin9%▲295.96%vs FY2024
ROE5.07%▲146.84%vs FY2024
Analyst consensus
RatingBuy
Target price$44.50▲33.03%
13
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $0.34 · Revenue est $130.25M
View